|
| Product Name: | (R)-(+)-Etomoxir sodium salt | | Synonyms: | (+)-etomoxir sodium hydrate;r(+)-2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid sodium salt hydrate;(+)-Etomoxir hydrate sodium salt;R(+)-2-[6-(4-Chlorophenoxy)hexyl]-oxirane-2-carboxylic acid hydrate sodium salt;Etomoxir(Nasalt);(R)-(+)-2-[6-(4-Chlorophenoxy)hexyl]-oxirane-2-carboxylic acid sodium salt;ANTI-EAPII;Etomoxir hydrate sodium | | CAS: | 828934-41-4 | | MF: | C15H20ClNaO4 | | MW: | 322.76 | | EINECS: | | | Product Categories: | | | Mol File: | 828934-41-4.mol |  |
| | (R)-(+)-Etomoxir sodium salt Chemical Properties |
| storage temp. | Inert atmosphere,2-8°C | | solubility | H2O: freely soluble | | form | White solid | | color | white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. | | InChIKey | WENJLJJSJDAJDN-QCUBGVIVSA-M |
| Hazard Codes | Xn | | Risk Statements | 22 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | HS Code | 2918999090 |
| | (R)-(+)-Etomoxir sodium salt Usage And Synthesis |
| Description | (R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1). | | Background | (R)-(+)-Etomoxir sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1(CPT-1).
Etomoxir (100 μM) has no effect on T cells cultured in high glucose. In contrast, there is a significant increase in apoptosis in etomoxir-treated cultures stimulated with antigen under low glucose conditions.
C57BL/6 mice treated with Etomoxir (15 mg/kg, i.p) reduce the infiltration of immune cells in the central nervous system. Only a small number of macrophages, activated microglia or T cells are present, while reducing the inflammatory response and Demyelinating reaction.
| | Application | (R)-(+)-Etomoxir sodium salt is an inhibitor of carnitine palmitoyltransferase I (CPT1); inhibits β-oxidation in mitochondria. Shown to inhibit cardiolipin biosynthesis from exogenous fatty acid in H9c2 cells. | | In Vitro | (R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir binds irreversibly to the catalytic site of CPT-1 inhibiting its activity, but also upregulates fatty acid oxidation enzymes. Etomoxir is developed as an inhibitor of the mitochondrial carnitine palmitoyltransferase-1 (CPT-1) located on the outer mitochondrial membrane. Etomoxir, in the liver can act as peroxisomal proliferator, increasing DNA synthesis and liver growth. Thus, etomoxir, in addition of being a CPT1 inhibitor could be considered as a PPARalpha agonist. Etomoxir is a member of the oxirane carboxylic acid carnitine palmitoyl transferase I inhibitors and has been suggested as a therapeutic agent for the treatment of heart failure. Acute Etomoxir treatment irreversibly inhibits the activity of carnitine palmitoyltransferase I. As a result, fatty acid import into the mitochondria and β-oxidation is reduced, whereas cytosolic fatty acid accumulates and glucose oxidation is elevated. Prolonged incubation (24 h) with Etomoxir produces diverse effects on the expression of several metabolic enzyme. | | In Vivo | (R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir is an inhibitor of free fatty acid (FFA) oxidation-related key enzyme CPT1. P53 interacts directly with Bax, which is inhibited by Etomoxir, further confirming the direct interaction of P53 and Bax, and the involvement of FAO-mediated mitochondrial ROS generation in db/db mice. Rats are injected daily with Etomoxir, a specific CPT-I inhibitor, for 8 days at 20 mg/kg of body mass. Etomoxir-treated rats display a 44% reduced cardiac CPT-I activity. The treatment of Lewis rats for 8 days with 20 mg/kg Etomoxir does not alter blood glucose, which is in line with comparable etomoxir-feeding studies. Similarly, Etomoxir feeding does not affect general growth characteristics such as gain in body mass, nor does it affect hindlimb muscle mass. However, heart mass and liver mass are both significantly increased by 11% in Etomoxir-treated rats. | | References | 1. Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36
2. Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003 Feb;44(2):415-23
3. Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724
4. Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419(2):447-55.
5. Rupp H, Zarain-Herzberg A, Maisch B. The Use of Partial Fatty Acid Oxidation Inhibitors for Metabolic Therapy of Angina Pectoris and Heart Failure. Herz, 2002, 27(7): 621-636.
6. Shriver L P, Manchester M. Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Scientific Reports, 2011, 1.
| | Description | Etomoxir Na (828934-41-4) is an irreversible inhibitor of mitochondrial carnitine palmitoyl transferase 1 (CPT1).1 It is widely used to study fatty acid oxidation. Etomoxir has been investigated as a therapeutic agent for heart disease2, diabetes3, and cancer4,5. Use of etomoxir in concentrations greater than 5 μM induces acute production of ROS with associated evidence of severe oxidative stress in proliferating T cells indicating a loss of specificity for CTP1 at these concentrations.6 200 μM etomoxir inhibited complex I of the electron transport chain.7 | | Uses | (+)-Etomoxir sodium salt hydrate has been used as an inhibitor of carnitine palmitoyltransferase 1 (CPT-1) in breast tumor cell lines and mice tumor. It has also been used as an inhibitor of fatty acid oxidation in human primary prostate epithelial cells and lymphocytes. | | General Description | (+)-Etomoxir sodium salt hydrate belongs to oxirane carboxylic acid group of compounds and mediates metabolic channeling of fatty acid precursors. It favors oxidative stress in T cells and prevents T cell differentiation. It inhibits fatty acid oxidation and promotes hunger and food intake. Etomoxir impairs myeloid-derived suppressor cells mediated tumor and could have potential therapeutic potential. | | Biochem/physiol Actions | Irreversible O-carnitine palmitoyltransferase-1 (CPT-1) inhibitor; PPARα activator | | storage | Store at -20°C | | References | 1) Agius et al. (1991), Stereospecificity of the inhibition of etomoxir of fatty acid and cholesterol synthesis in isolated rat hepatocytes; Biochem. Pharmacol. 42 1717
2) Lionetti et al. (2011), Modulating fatty acid oxidation in heart failure; Cardiovasc. Res, 90 202
3) Huebinger et al. (1997), Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure, and substrate oxidation in NIDDM; Horm. Metab. Res.?29 436
4) Pike et al. (2011), Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells; Biochim. Biophys. Acta 1807 726
5) Samudio et al. (2010), Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction; J. Clin. Invest. 120 142
6) O’Connor et al. (2018), The CPT1a inhibitor, etomoxir, induces severe oxidative stress at commonly used concentrations; Sci. Rep.?8 6289
7) Yao et al. (2018), Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation; PLoS Biol. 16 e2003782 |
| | (R)-(+)-Etomoxir sodium salt Preparation Products And Raw materials |
|
